β blockers for aortic regurgitation

β blockers for aortic regurgitation

β-Blockers in Aortic Regurgitation (AR)

Bottom line:
β-blockers are generally avoided in chronic severe aortic regurgitation, particularly when the patient is asymptomatic or has preserved left ventricular (LV) function.

---

Pathophysiological rationale

• AR severity is time-dependent.
• β-blockers prolong diastole by reducing heart rate.
• Longer diastolic duration → increased regurgitant volume → higher LV volume overload.
• This may worsen LV dilatation and dysfunction over time.

---

Chronic Aortic Regurgitation

Not routinely recommended, especially in:

• Severe AR
• Normal sinus rhythm
• Preserved LV systolic function

Preferred agents for afterload reduction:

• ACE inhibitors / ARBs
• Dihydropyridine calcium-channel blockers (e.g., nifedipine)

---

Situations where β-blockers may be used

β-blockers are not absolutely contraindicated and may be appropriate in selected contexts:

1. Coexisting indications
   • Hypertension (when other agents are insufficient)
   • Coronary artery disease
   • Prior myocardial infarction
   • Arrhythmias requiring rate control (e.g., atrial fibrillation)
2. Aortic root disease
   • Marfan syndrome
   • Bicuspid aortic valve with aortopathy
     β-blockers may slow aortic root dilatation (benefit relates to the aorta, not AR itself).
3. Acute severe AR (temporary use)
   • Rare and controversial
   • Usually avoided; tachycardia may actually be beneficial in acute AR

---

Acute Aortic Regurgitation

β-blockers are contraindicated

• Need short diastole to limit regurgitation
• Management favors:
  • Vasodilators (e.g., nitroprusside)
  • Inotropes if needed
  • Urgent surgery

---

Guideline perspective (ESC / ACC-AHA aligned)

• No recommendation for routine β-blocker use in chronic AR
• Use only if another compelling indication exists

---

read more

read more